tradingkey.logo

Drugs Made In America Acquisition II Rights Exp 16 Sep 2030

DMIIR
0.120USD
0.0000.00%
交易中 美東報價延遲15分鐘
0.00總市值
--本益比TTM

Drugs Made In America Acquisition II Rights Exp 16 Sep 2030

0.120
0.0000.00%

關於 Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 公司

Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.

Drugs Made In America Acquisition II Rights Exp 16 Sep 2030簡介

公司代碼DMIIR
公司名稱Drugs Made In America Acquisition II Corp
上市日期Sep 25, 2025
CEOStockwell (Lynn)
員工數量- -
證券類型Right
年結日- -
公司地址1 East Broward Boulevard
城市FT LAUDERDALE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33301
電話19548703099
網址
公司代碼DMIIR
上市日期Sep 25, 2025
CEOStockwell (Lynn)

Drugs Made In America Acquisition II Rights Exp 16 Sep 2030公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 2月6日 週五
更新時間: 2月6日 週五
持股股東
股東類型
持股股東
持股股東
佔比
其他
100.00%
持股股東
持股股東
佔比
其他
100.00%
股東類型
持股股東
佔比
其他
100.00%

機構持股

更新時間: 2月1日 週日
更新時間: 2月1日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
3
958.51K
0.00%
+958.51K

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
暫無數據
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
KeyAI